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A B S T R A C T
Interferon gamma has long been studied as a critical mediator of tumor immunity. In recent years, the com-
plexity of cellular interactions that take place in the tumor microenvironment has become better appreciated in
the context of immunotherapy. While checkpoint inhibitors have dramatically improved remission rates in
cancer treatment, IFN-γ and related effectors continue to be identified as strong predictors of treatment success.
In this review, we provide an overview of the multiple immunosuppressive barriers that IFN-γ has to overcome
to eliminate tumors, and potential avenues for modulating the immune response in favor of tumor rejection.
1. Introduction
In recent years, we have witnessed enormous growth in the appli-
cation of immunotherapy to treat various malignancies. Extending from
a standard of surgery, chemo- and radiation therapies, remarkable
improvements in response rates have been observed through the ap-
plication of various antibody [1,2] and cell based therapies [3–5]. A
major contributing factor to the efficacy of these treatments is mediated
by the secretion of cytokines which activate and instruct cells of the
immune system, as well as exert direct cytotoxic effects on tumor cells
themselves. It was a consequence of the highly potent effects exerted by
cytokines that they were first explored as treatments for different ma-
lignancies. The earliest FDA approved cytokine treatment was re-
combinant Interleukin-2 (IL-2), which arose from clinical trials de-
monstrating responses in renal cell carcinoma (RCC) and metastatic
melanoma [6]. However, despite promising responses, these therapies
encountered severe toxicities which curbed their acceptance as a viable
therapy. Indeed, given the broad cytokine-sensitivity of cells spread
throughout the body, including cells of hematopoietic and non-hema-
topoietic origin, systemic administration of cytokines is not well tol-
erated due to acute [7,8] and chronic adverse events [9,10]. Re-
cognizing the challenges of systemic toxicity, efforts were undertaken
to localize the delivery of cytokines, and to better understand the im-
munological activity of cells found within the tumor [11,12]. It was
appreciated early on, that a good correlation existed between the anti-
tumor activity of tumor infiltrating lymphocytes (TILs), and their ca-
pacity to secrete IFN-γ [13–15]. In very early adoptive cell therapy
trials, transfusion of ex vivo expanded TILs and treatment with systemic
IL-2 produced regression of tumors, and this was suspected to be a
function of IFN-γ secretion [13,16]. Attempts at exploiting the potency
of IFN-γ have yielded conflicting results, with both anti- and pro-tu-
morigenic effects being observed. Unfortunately, intravenous or sub-
cutaneous administration of IFN-γ has not improved the outcome of
melanoma [17], renal cell carcinoma [18], leukemia [19], pancreatic
carcinoma [20], breast cancer [21], and colon cancer [22].
2. IFN-gamma biology
Following its discovery in 1965 as a soluble antiviral factor released
by phytohemagglutinin-stimulated PBMC [23], Interferon gamma (IFN-
γ) became well known for its pleiotropic immunomodulatory effects on
both innate and adaptive immunity. As a soluble homodimer [24], IFN-
γ has been shown to be secreted primarily by activated lymphocytes
such as CD4 and CD8 T cells [25,26], gamma delta T cells [27], as well
as NK [28,29] and NK T cells [30]. Additional sources include B cells
[31–34] and antigen presenting cells (macrophages [35], monocytes
[36] and dendritic cells [37]). IFN-γ signals through a heterodimer of
IFNgR1/2, whose expression is broadly distributed among hemato-
poietic and non-hematopoietic cells alike [38]. Signaling is tightly
regulated through controlled expression of IFNgR2 with stable expres-
sion of IFNgR1 among different cells [39,40]. This differential regula-
tion of receptor subunits is thought to influence the balance between
the mitogenic and growth inhibitory effects of IFN-γ [41]. Numerous
antitumor effects of IFN-γ have been described, and include the reg-
ulation of antigen presentation, promotion of inflammatory and che-
motactic signals [42,43], activation and polarization of responding
leukocytes, as well as direct antiproliferative [44–46] and anti-
angiogenic effects [47] (Fig. 1). Induction of angiostatic chemokines,
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CXCL9 (MIG), CXCL10 (IP-10) and CXCL11 (I-TAC) by IFN-γ block
neovascularization and also recruit effector leukocytes [48–50]. IFN-γ
also antagonizes suppressive cytokine expression (TGF-β, IL-10), and
favors the induction of IL-12 expression in macrophages [51,52]. IFN-γ
signaling is able to repress tumorigenic M2-differentiation of macro-
phages [53]. Proapoptotic effects have also been attributed to IFN-γ
[54,55]. Induction of TRAIL and its cognate receptor, a potent mediator
of apoptosis in tumor cells, is also upregulated by IFN-γ [56,57]. Direct
induction of caspase-1 and -8 in tumor cells by IFN-γ is also an effective
inducer of apoptosis [58,59]. Tumor cell apoptosis is also induced
through upregulation of Fas and FasL [60,61]. Generation of reactive
oxygen species and nitric oxide are potent cytotoxic effectors that are
also regulated by IFN-γ [62,63].
Secretion of IFN-γ by tumor infiltrating lymphocytes (TILs) results
in the upregulation of antigen presentation in dendritic cells and
macrophages [42,64]. IFN-γ also upregulates specific components of
the immunoproteasome thereby producing unique peptides for MHC-I
presentation [65–67]. In macrophages and dendritic cells, IFN-γ upre-
gulates MHC-II expression through activation of MHC class II transac-
tivator (CIITA) [68,69]. Acting on APC, IFN-γ upregulates expression of
costimulatory molecules and cytokines which are necessary for acti-
vation of T cells [70]. In tumor cells, IFN-γ also induces the expression
of MHC-I and STAT1 associated cyclin dependent kinase resulting in
apoptosis of tumor cells and immune recognition [47,71]. Underscoring
the requirement for IFN-γ in eliminating tumors, many studies have
utilized various genetic and antibody blocking approaches to demon-
strate both the direct [72,73] and indirect [74] aspects of IFN-γ-medi-
ated tumor suppression.
Contrary to the many antitumorigenic effects exerted by IFN-γ,
protumoral effects have also been observed. This activity is thought to
occur primarily through a loss of IFN-γ signaling sensitivity, reduced
antigen presentation [75] and induction of indolamine 2, 3-dioxy-
genase (IDO) [76] and checkpoint inhibitors [77]. Resistance to IFN-γ
mediated cytotoxicity and cytostasis can be mediated by mutations in
JAK-STAT signaling and antigen processing proteins [78–80]. A loss of
IFN-γ signaling reduces MHC-I induction. Additionally, tumor-asso-
ciated methylation of the IFN-γ promoter reduces MHC-I expression in
tumors tissues [81]. The loss of IFN-γ responsiveness in tumors is as-
sociated with lower antigenicity [72]. Along with the aberrant ex-
pression of the coinhibitory molecule, PD-L1, in tumor tissues [82,83],
its expression is also induced through exposure to IFN-γ [84,85]. In-
terestingly, the duration of IFN-γ exposure also dictates the respon-
siveness of tumors to immune suppression, with chronic exposure
producing a loss of sensitivity known as “adaptive resistance” [77].
3. IL-12 biology
A major inducer of IFN-γ is IL-12, and the expression of both genes
is coordinated (i.e. IL-12 induces IFN-γ, and IFN-γ induces IL-12). IL-12
exerts potent immunomodulatory effects of cells of innate and adaptive
immunity. Secreted as a biologically active 70 kDa heterodimer, IL-12 is
composed of disuphide linked alpha (p35) and beta (p40) subunits
[86]. Binding to its cognate heterodimeric IL12RB1/2 receptor induces
signaling via Jak-mediated phosphorylation of STAT4 [87,88]. Sig-
naling through STAT4 induces the expression of IFN-γ [89] (Fig. 1).
During the activation of naïve CD8 T cells, IL-12 provides a third signal,
alongside TCR and CD28 costimulation which improves clonal expan-
sion and cytolytic activity [90,91]. Proliferative responses to IL-12 can
be influenced by induction of CD25, a necessary component of IL-2
signaling [92]. Other significant effects of IL-12 include the induction of
T cell, NK and NK T cell cytolytic activity, and enhanced antigen pre-
sentation [93]. Many of the IL-12 mediated effects are exerted through
inducible IFN-γ expression and the skewing of CD4 T cells to a Th1
phenotype [94,95]. Induction of IFN-γ in T cells initiates a positive
feedback loop whereby IFN-γ sensitive APCs are primed to produce
additional IL-12 [96]. Synergy between IL-12 and IL-18 has also been
demonstrated to strongly induce IFN-γ in B cells [33,34]. IL-12, and
other cytokines have been shown to enhance the CTL activity of T cells
through increasing the sensitivity to weak or self antigens [97,98]. This
has been one explanation for the development of autoimmunity
Fig. 1. IFN-γ exerts pleiotropic effects to
overcome tumor immunosuppression.
The tumor microenvironment exerts strong
antagonism toward infiltrating lymphocytes
through various cytokine, receptor and meta-
bolic processes. To overcome these pathogenic
barriers, IFN-γ and IL-12 operate in concert to
amplify an anti-tumoral response through
dampening immunosuppressive signals and
increasing cytolytic effector function and di-
rect antiproliferative signals.
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developing during microbial infections, as there is often an abundance
of IL-12 present at the site of infection [99]. IL-12 is mainly produced
by APCs (dendritic cells, monocytes, macrophages and B cells) and can
be activated by various TLR signals. This effect is currently being ex-
plored as a potential mechanism to boost anti-tumor immunity
[100–103]. However, opposing effects have also been observed where
TLR ligands can promote a tolerogenic response in DCs through the
upregulation of IL-10 and TGF-β [104]. Signals that inhibit IL-12 pro-
duction include IL-10 and TGF-β, and these same signals also inhibit
IFN-γ [105,106].
4. Tumor microenvironment
As our understanding of tumor immunology has advanced, we have
appreciated that various malignancies exert profoundly suppressive
cues toward anti-tumor immune cells [107–110] (Fig. 1). The tumor
microenvironment, once formed, is a formidable obstacle for innate and
adaptive immunity to overcome. Prominent barriers to elimination in-
clude the tumor promoted conditioning of immunosuppressive cells
such as Treg, MDSC and M2-macrophages, as well as limited antigen
presentation, upregulation of T cell suppressive signals (e.g. PD-1/L1
and CTLA-4) and metabolic cues.
One prominent inhibitory molecule that is produced in tumors, and
is associated with poor outcome, is IL-10, a potent anti-inflammatory
cytokine [111,112]. Within the tumor microenvironment, tumor cells
themselves have been shown to express IL-10 [113,114] in addition to
infiltrating hematopoietic cells of myeloid [115] and lymphoid origin
[116]. Regulatory CD4 T cells (Treg) are also significant sources of IL-10
in tumors, and their presence in high proportion relative to CD8 T cells
is indicative of poor prognosis [117–119]. Opposing effects of IL-10
have been observed, where a decrease in antigen presentation is de-
tected in CD4 T cells [120,121] and macrophages, and a stimulatory
effect is observed in CD8 T cells [122–125]. Cross-regulation between
cytokines has been shown to exist between IL-10 and IFN-γ [126].
Depending on the timing and magnitude of expression, both cytokines
can interfere with one another. IL-10 has been clearly shown to mitigate
the effects of IFN-γ in antigen presentation through down regulation of
MHC-II, costimulatory molecules and proteolytic enzymes [127–132].
This effect is mediated by interference with IFN-γ signaling through the
Jak-STAT and NFkB transcriptional pathways [133,134]. In macro-
phages, IL-10 mediates downregulation of costimulatory molecules and
MHC-II through the induction of March-1, an E3 ubiquitin ligase, which
specifically targets these critical molecules for proteolytic degradation
[135]. Mirrored in T cells, IL-10 also inhibits tyrosine phosphorylation
and activation of CD28 [136]. IFN-γ exerts a strong antagonism towards
IL-10 through transcriptional suppression [137]. Suppression of IL-10
in CpG-stimulated DCs was accompanied by a strong induction of IL-12
expression [138]. A number of studies have also provided evidence for
the suppressive effect of IFN-γ towards Treg stability [32,139,140].
Another contributor to tumor immunosuppression is myeloid de-
rived suppressive cells (MDSC), which are activated through in-
flammatory processes and serve to dampen immune responses. MDSC
secrete various immunosuppressive molecules including arginase
(ARG1), iNOS-2, TGF-β, IL-10, COX2 and indoleamine 2, 3-dioxygenase
(IDO) which sequesters tryptophan and decreases L-selectin expression
on T cells [141–144] (Fig. 1). Of interest is the fact that IFN-γ induces
many of these genes, thus it’s actions enhance the host immune re-
sponse but also damped the response if IFN-γ signaling is prolonged.
Both arginase and iNOS2 utilize L-arginine as a substrate, and thus
deplete its availability to T cells, which limits their functional capacity.
Surface expression of ADAM17 on MDSC cleaves L-selectin (CD62 L)
and interferes with homing to lymph nodes [145]. Production of ROS
can interfere directly with TCR activation and chemokine activity
through protein nitration [146,147] (Fig. 1). In macrophages, nitration
of STAT1 has also been suggested to limit IFN-γ inducible signaling
[148]. Additionally, MDSC promote tumorigenesis through expression
of VEGF, bFGF, Bv8 and MMP9 which have been shown to be angio-
genic [149,150].
Tumor-associated macrophages are another significant leukocyte
population commonly found in tumors, and can be generally defined by
their pro- or anti-inflammatory function [151,152]. Pro-inflammatory
M1-type macrophages can suppress tumor growth through production
of IL-1, IL-6, IL-12, TNF-α and upregulation of antigen presentation and
costimulatory molecule expression [153]. Their development is pro-
moted by the presence of IFN-γ, GM-CSF or LPS [154]. In contrast, anti-
inflammatory M2-type macrophages produce abundant IL-4, IL-10,
TGF-β, prostaglandin E2 and VEGF which favor tumorigenesis. En-
vironmental factors which influence the development of M2-type
macrophages include tumor secreted IL-4, IL-13, IL-10 and M-CSF
[152]. Additionally, their development is also favored by exposure to
lactic acid and contact with apoptotic cells or damage-associated mo-
lecular patterns (DAMPs) which are distributed through tumor tissue
[155,156]. The presence of M2-type macrophages is correlated with
poor prognosis in a variety of malignancies [157,158].
Co-inhibitory molecules are normally upregulated on activated T
cells following stimulation. These signals serve to limit excessive in-
flammation, and exert negative feedback. In animals lacking co-in-
hibitory molecules, or during administration of checkpoint inhibitors in
the clinic, autoimmune-like pathologies have been documented [159].
However, in tumors, these regulatory mechanisms limit the develop-
ment of a robust response. Consequently, a number of co-inhibitory
signaling molecules (PD-1/-L1, CTLA-4 and others) have been in-
vestigated in the context of boosting anti-tumoral immunity [160,161].
The expression of these markers correlates well with the degree of
unresponsiveness. PD-1 is expressed on the surface of activated T cells,
and directly attenuates CD28-mediated signaling through the recruit-
ment of phosphatases to TCR-proximal signaling complexes [162]
(Fig. 1). CTLA-4 is also upregulated on the surface of activated T cells,
but interferes with CD28 costimulation through distinct mechanisms
from PD-1 [162,163]. During chronic viral infection, or in tumors,
where persistent exposure to antigen can occur, the degree to which T
cells are stimulated with antigen, corresponds with their loss of func-
tional capacity [164]. Continual TCR signaling leads to a reduced rate
of remethylation at the PD-1 locus, thereby reinforcing expression and
potentiating inhibitory effects [165]. A progressive loss of proliferative
capacity and IL-2 production by T cells is followed by a failure to
produce TNF-α and IFN-γ. This process, termed exhaustion, is not a
terminal cell fate, and can be reversed in vivo through the blockade of
co-inhibitory receptors [161,166]. Indeed, FDA-approved monoclonal
antibodies directed against PD-1, PD-L1 or CTLA-4 have proven effec-
tive at interfering with the immunosuppressive effects that are exerted
by tumor tissues on cytotoxic T cells [167]. Additional co-inhibitory
receptors such as Lag-3, Tim-3, BTLA, CD160 and 2B4 are being ex-
plored in clinical and pre-clinical development [168,169].
Another hallmark of the tumor microenvironment is dysregulated
metabolism, where glucose is utilized through aerobic glycolysis in-
stead of oxidative phosphorylation. This process, known as the Warburg
effect, produces considerable secreted lactate (lactic acid) which signals
though GPR81 on surrounding tumor cells to induce PD-L1 expression
[170] (Fig. 1). Lactate also strongly inhibits the expression of cytolytic
effectors granzyme B and IFN-γ in CD8 T cells [171]. Additionally,
given the rapid consumption of glucose by tumor cells, it’s reduced
availability limits T cell function [172]. This metabolic restriction is
sensed by the metabolic enzyme and RNA binding protein, GAPDH,
which, in turn, binds to the AU-rich regions of the 3′ UTR of IFN-γ
transcripts and reduces expression [173]. Interestingly, glucose depri-
vation exerts a stronger inhibitory effect on IFN-γ expression than IL-2
[174].
5. Overcoming immunosuppression
With increasing usage of checkpoint inhibitors, our understanding
J.D. Burke and H.A. Young Seminars in Immunology 43 (2019) 101280
3
of their mechanistic role in facilitating immune-mediated tumor
clearance is becoming better understood. Certainly, an IFN-γ-associated
gene signature was shown to be necessary for clinical benefit during
PD-L1 blockade [175]. In a recent structural study of IFNγR activation,
Mendoza et al. identified synthetic IFN-γ mimetics that were able to
specifically activate signaling to upregulate MHC-I expression in tumor
cell lines, without upregulating the immunosuppressive molecule, PD-
L1 [176]. This decoupling of immunostimulatory and im-
munosuppressive effects certainly opens exciting possibilities for de-
velopment. A recent study by Garris et al. highlighted the critical
function of PD-1 blockade in enabling the amplification of IL-12 and
IFN-γ reciprocal regulation to permit an effective anti-tumoral response
[177]. In the context of adoptive T cell therapy, ex vivo activation and
expansion of T cells in the presence of IL-12 has improved CTL activity
[178–180]. This effect has been attributed to dampening the negative
regulatory effects exerted by IFN-γ. Specifically, a reduction of PD-1
expression in T cells limited the suppressive effects of IFN-γ-inducible
PD-L1 expression in tumor tissues. Additionally, a decrease in IFN-γR2
expression on expanded T cells also reduced the negative autocrine
effects of IFN-γ expression [181].
Given the importance of IL-12 in augmenting IFN-γ expression, and
the cytolytic activity of T cells, its incorporation into immunotherapy
regimens is still being pursued with emphasis on targeted delivery.
Systemic administration of IL-12 has shown limited success, with nu-
merous adverse events being observed in clinical trials, likely a con-
sequence of off-target effects, as well as poor pharmacokinetics
[182–184]. To target IL-12 expression to the tumor microenvironment,
plasmids encoding IL-12 have been introduced via electroporation
[185,186], intratumoral injection of viral vectors encoding IL-12 [187],
engineered tumor-specific T cells expressing IL-12 [188–195] and in-
tratumoral injection of microspheres containing slow-release IL-12
[196,197]. Recent attention has been given to an IL-12-fused anti-his-
tone antibody (NHS-IL12) which targets sites of cell necrosis where free
cellular DNA is abundant. When combined with radiation therapy in a
mouse model, a significant anti-tumor immune response was observed
alongside increased survival [198,199]. More recently, in a phase I
clinical trial, NHS-IL12 was well tolerated, and was accompanied by an
indication of anti-tumor immunity [200].
6. Conclusions
Coupled with an increasingly sophisticated understanding of anti-
tumor immunity, the powerful tools of molecular immunology are al-
lowing us to develop innovative new therapies to treat cancer. We have
already seen encouraging improvements in potency of immunotherapy,
and it is clear that many targets still exist for intervention. Given the
complexity of tumor-mediated immunosuppression, it is very likely that
integrating multiple facets of tumor immunity will be necessary to
overcome the existing barriers. The pleiotropic nature of IFN-γ under-
scores this, and certainly maintains it as an attractive candidate for
development, despite previous challenges. To better reflect a natural
mechanism of localized activity, it is critical that the delivery of the
right treatment is to the right place. Indeed, the continued honing of
immunotherapy will undoubtedly yield more effective and better tol-
erated therapies in the clinic.
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